Rush University Medical Center

 

Rush University Medical Center
Avatar

2020 Update on EGFR+ mNSCLC: How Effective Is the Addition of Newly Approved Ramucirumab to Erlotinib? Results from the RELAY Study

By Rush University Medical Center FEATURING Mary Fidler
By Rush University Medical Center FEATURING Mary Fidler
487 views
September 11, 2020
0 Comments
Login to view comments. Click here to Login
Videos
05:12
Rush University Medical Center

Current Unmet Needs and Challenges in 1L Treatment Approaches for EG…

Feat. M. Fidler
10:22
Rush University Medical Center

Clinical Implications of CheckMate 9ER Data: Applications for Practi…

Feat. A. Tan
06:50
Rush University Medical Center

Post-Operative Therapy in NSCLC

Feat. M. Fidler
09:39
Rush University Medical Center

The Impact of Hormonal Therapies for Breast and Prostate Cancers on …

Feat. T. Okwuosa
05:28
Rush University Medical Center

HER2CLIMB Data on TKIs for HER2+ MBC: How Effective Is Tucatinib? Wh…

Feat. R. Rao
12:54
Rush University Medical Center

2020 Update on EGFR+ mNSCLC: How Effective Is the Addition of Newly …

Feat. M. Fidler
32:28
Rush University Medical Center

Rush Cancer Care During COVID-19: Have Outpatient Visits Decreased? …

Feat. M. Levy
34:24
Rush University Medical Center

Managing COVID-19 at Rush Medical Center: In Which Situations Would …

Feat. M. Yoder
11:22
Rush University Medical Center

COVID-19, CV Risk Factors and Racial Differences in Mortality: What …

Feat. K. Williams
12:56
Rush University Medical Center

COVID-19 & African Americans: How Can We Recalibrate What's…

Feat. C. Yancy
07:00
Rush University Medical Center

COVID-19: Treatment with ACE Inhibitors and Angiotensin Receptor Blo…

Feat. A. Santos Volgman
13:25
Rush University Medical Center

What Are the Consequences of the COVID-19 Pandemic on Interventional…

Feat. C. Kavinsky
19:49
Rush University Medical Center

COVID-19 Coagulopathy: Whom to Anticoagulate and How? What Agents to…

Feat. S. Jain